Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Aug
06
Today In Oncology
Early Trial Supports KRAS Vaccine Strategy for Pancreatic Cancer Interception
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML
Fusobacterium Positivity Predicts Relapse Risk and Limited Benefit From Adjuvant Chemotherapy in Colorectal Cancer
Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo